2.3200 +0.02 (0.87%)
After hours: 4:03PM EST
|Bid||2.3000 x 1000|
|Ask||2.3200 x 1400|
|Day's Range||2.2861 - 2.4848|
|52 Week Range||2.2861 - 5.7800|
|Beta (5Y Monthly)||1.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2020 - Feb 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
VIVUS, Inc. (VVUS), a biopharmaceutical company, today announced the publication of a new study from the Toolbox Trial (NCT01922934), a real-world clinical trial conducted in urban safety-net primary care clinics offering patients a “toolbox” of cost-effective weight management tools. The study, published in the Journal of General Internal Medicine1 (JGIM), found that a higher proportion of subjects who initially selected Qsymia from the toolbox or added it to their weight management plans during the study period achieved at least a 5% weight loss compared with subjects who never used Qsymia.
CAMPBELL, Calif., Jan. 02, 2020 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer, will.
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted a new stockholder rights plan to replace the Company’s stockholder rights plan that expired in accordance with its terms on November 9, 2019. Under the new rights plan, the terms of which are substantially similar to the terms of the Company’s prior rights plan, VIVUS will issue a dividend of one right for each share of its common stock held by stockholders of record as of the close of business on January 13, 2020.
If you're interested in VIVUS, Inc. (NASDAQ:VVUS), then you might want to consider its beta (a measure of share price...
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced the results of a pharmacokinetic (PK) and pharmacodynamic (PD) study (NCT02714062) demonstrating that Qsymia® (phentermine and topiramate extended-release) capsules CIV has favorable pharmacokinetic, efficacy, and safety/tolerability profiles when used for eight weeks to treat adolescents with obesity. The study was conducted in order to establish dosing levels for the ongoing Phase 4 post-marketing study of Qsymia in obese adolescents.
CAMPBELL, Calif., Nov. 25, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS,.
Shares of Vivus Inc. rose 9% in morning trading after the drugmaker said its weight-loss drug Qsymia can reduce binging frequency for patients with binge-eating disorder or bulimia nervosa. The FDA first approved Qsymia as a weight-loss treatment for obese patients in 2012. Sales of the drug declined 4% to $9.58 million in the third quarter of 2019, compared to $9.99 million in the like-quarter in 2018. Vivus stock is up 28% year-to-date. The S&P 500 has gone up 24%.
-Data published in International Journal of Eating Disorders show patients in the Qsymia group had 75% decrease in binge day frequency compared with 19% for placebo-.
By John Vandermosten, CFA NASDAQ:VVUS READ THE FULL VVUS RESEARCH REPORT Third Quarter 2019 Results Vivus, Inc. (NASDAQ:VVUS) released quarterly results on November 5, 2019 and provided an update of financial and operational results for the third quarter. During the three month interval topline growth declined less than 1%, while adjusted earnings improved more than anticipated due to lower cost
CAMPBELL, Calif., Nov. 05, 2019 -- VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of.
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resigned from its Board of Directors and all of its committees in order to increase their focus on other personal business interests. Mr. Roberts and Mr. Shaw joined the Board of Directors in September 2015. “Serving as a director on the Board of a publicly traded company, especially one that is significantly transforming its business model and continually evaluating its complex capital structure, is a substantial time commitment, and we appreciate the substantive contributions that Eric and Allan have made to VIVUS over the past four years,” said David Y. Norton, Chairman of VIVUS’ Board of Directors.
CAMPBELL, Calif., Oct. 22, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2019.
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, announced today that John Amos, Chief Executive Officer, will participate in a panel discussion at the Cleveland Clinic 2019 Medical Innovation Summit, which is taking place October 21 – 23 in Cleveland. The panel discussion, titled “Beneath the Epidemic. “The rapidly growing obesity epidemic is becoming a greater threat to the long term health of the global population, resulting in lower quality of life, greater medical challenges and higher out-of-pocket insurance costs,” said John Amos, Chief Executive Officer of VIVUS.
By John Vandermosten, CFA NASDAQ:VVUS Vivus, Inc. (NASDAQ:VVUS) announced the pay down of $48.6 million of its senior secured notes due 2024. The securities were yielding 10.375% and their early retirement is expected to save Vivus $10.5 million over the term of the loan. Vivus has held substantial cash on its balance sheet and now that they are close to operating free cash flow breakeven,
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denmark, Finland, Iceland, Norway, and Poland (the “Concerned Member States”) have accepted the Marketing Authorization Application (the “MAA”) for Qsymia (phentermine and topiramate extended-release) on a decentralized basis, with Sweden acting as the lead Concerned Member State, also known as the Reference Member State, for purposes of assessing the MAA. Under the decentralized MAA procedure, the regulatory authorities in each of the Concerned Member States may simultaneously provide Marketing Authorization for use of a product within those specific countries.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
-Reduction of $48.6 million of Secured Debt will result in total interest savings of $10.5 million--Organizational change streamlines commercial operations- CAMPBELL,.
CAMPBELL, Calif., Aug. 28, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS,.
-Conference in Seoul provides opportunity to introduce an international audience to the clinical safety and benefits of Qsymia following its approval in the Republic of Korea-.
Vivus, Inc. (VVUS) released second quarter results on August 6, 2019 and provided an update of financial and operational results for the April to June period. During the three month interval the company achieved topline growth of 23%, launched online payments for Qsymia, assumed full responsibility for Pancreaze in Canada from Janssen and launched its Phase IV Qsymia study in adolescents. Following the end of the quarter, Vivus announced the approval of Qsymia in South Korea and disseminated results of a study illustrating the weight loss benefits of Qsymia used in conjunction with gastric sleeve surgery.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. iBio (NYSE: IBIO ) shares were down 14% to ...
“Patients with a BMI of 50 or greater generally benefit from bariatric surgery but have higher surgical risk and increased perioperative morbidity compared with patients with lower BMI,” said Jamy Ard, MD, Professor, Epidemiology and Prevention at Wake Forest School of Medicine and lead author on the publication. “In an effort to reduce these risks, we undertook a pilot study to assess the feasibility and impact of using the drug before and after LSG surgery. Study results show that patients taking it lost significantly more weight before surgery and had improved outcomes with respect to weight loss and BMI than those not on AOM.
Every investor in VIVUS, Inc. (NASDAQ:VVUS) should be aware of the most powerful shareholder groups. Generally...